Circulating platelet-derived microRNAs as potential biomarkers of STEMI in patients with hypertension
Background: Circulating extracellular platelet-derived microRNAs have been actively studied over the last decade as promising biomarkers of cardiovascular disease (CVD), since platelet activation plays a key role in the pathogenesis of CVD. The aim of the study:To compare platelet-derived microRNA profiles in patients with uncomplicated hypertension (HT) and in patients with HT and acute myocardial infarction with ST-segment elevation (STEMI). Materials and methods: The study included 20 patients with uncomplicated HT and 15 patients with HT and STEMI. At least 90% of the participants in each group received antiplatelet therapy. A blood sample was collected from each patient in a CTAD anticoagulant tube and blood plasma was obtained by two-step centrifugation. The degree of hemolysis of the plasma samples was determined spectrophotometrically. MicroRNAs were isolated from plasma samples and used for reverse transcription and quantification of relative levels of eight main circulating extracellular platelet-derived microRNAs (miR-223-3p, miR-126-3p, miR-21-5p, miR-24-3p, miR-320a-3p, miR-191-5p, miR-150-5p and miR-23a-3p) by quantitative PCR using the TaqMan Advanced technology (Thermo Fisher Scientific, USA). Normalized relative expression levels for each miRNA were calculated. Differences were considered statistically significant at p < 0.05 (Mann-Whitney test). Results: Patient groups did not differ in age, BMI, platelet count, lipid profile and degree of hemolysis of plasma samples. No differences were found between the ratio of platelet-derived and erythrocyte-derived microRNA between patient groups. No statistically significant differences were found in the relative levels of circulating microRNA between the study groups. Principal component analysis and heatmap analysis of microRNA expression in the samples showed a division of the samples into groups based more on the degree of hemolysis than on the presence/absence of STEMI. Conclusion: In the studied sample of hypertensive patients, the effect of hemolysis of plasma samples on circulating platelet-derived microRNA profiles was more significant than the presence of STEMI
Zhelankin AV, Stonogina DA, Akselrod AS. Circulating platelet-derived microRNAs
as potential biomarkers of STEMI in patients with hypertension. Research Results in Biomedicine.
2024;10(3):351-373. Russian. DOI: 10.18413/2658-6533-2024-10-3-0-3
While nobody left any comments to this publication.
You can be first.